TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39501183
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg aspirin daily
Study: 35215405
Drug: NMN (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMN (250 mg) administered once a day for 12 weeks
Study: 34470137
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200 mg daily)
Study: 34470137
Drug: 17-alpha-hydroxyprogesterone caproate
Normalized name: 17-alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-alpha-hydroxyprogesterone caproate (17OHP-C) (250 mg intramuscular weekly)
Study: 33741236
Drug: Weekly voice
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly voice therapy
Study: 32016386
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous zoledronate (ZZ, n = 16)
Study: 37852737
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone
Study: 37976067
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/d)
Study: 35372875
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil and/or aspirin
Study: 33408073
Drug: Circulating 27‐OHC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating 27‐OHC at or above the fourth quartile (?201 ng/mL)
Study: 33408073
Drug: Circulating 27‐OHC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating 27‐OHC below the first quartile (<138 ng/mL)
Study: 34089503
Drug: ctDNA-guided adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: ctDNA-guided adjuvant chemotherapy (AC)
Study: 33563173
Drug: Gabapentin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (800 mg/day)
Study: 38770804
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy
Study: 35409640
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence
Study: 35405631
Drug: Laser auriculotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser auriculotherapy (10 sessions, twice a week)
Study: 34825617
Drug: Titrated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated group (received propofol at a rate of 1 mg/kg/min until the Observer's Assessment of Alertness/Sedation scale score reached 1 point)
Study: 34825617
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (received 2 mg/kg propofol at a rate of 250 mg/min)
Study: 35562711
Drug: Memantine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (5 mg/day initially, increased to 20 mg/day over 4 weeks)
Study: 36153153
Drug: AVP booster
Normalized name: AVP-21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP booster dose in Group A (on schedule)
Study: 36153153
Drug: AVP booster
Normalized name: AVP-21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP booster dose in Group B (not on schedule for ≥2 years)
Study: 36153153
Drug: AVP booster
Normalized name: AVP-21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP booster doses
Study: 32449130
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day resveratrol
Study: 33184629
Drug: Intravenous d6-α-tocopherol
Normalized name: D6 tetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous d6-α-tocopherol with 600-kcal defined liquid meal (40% fat)
Study: 33184629
Drug: Intravenous d6-α-tocopherol
Normalized name: D6 tetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous d6-α-tocopherol with 600-kcal defined liquid meal (0% fat)
Study: 33184629
Drug: Oral d3-α-tocopherol
Normalized name: alpha tocopherol / cholecalciferol / vitamin A Injectable Solution [Vital E- A + D3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral d3-α-tocopherol with 600-kcal defined liquid meal (40% fat)
Study: 33184629
Drug: Oral d3-α-tocopherol
Normalized name: alpha tocopherol / cholecalciferol / vitamin A Injectable Solution [Vital E- A + D3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral d3-α-tocopherol with 600-kcal defined liquid meal (0% fat)
Study: 33184629
Drug: Oral d3-α-tocopherol
Normalized name: alpha tocopherol / cholecalciferol / vitamin A Injectable Solution [Vital E- A + D3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral d3-α-tocopherol with 0% fat DLM followed by a 12-h fast (0% fat-fast)
Study: 34520092
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy - Long (CBT-L)
Study: 34520092
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy - Brief (CBT-B)
Study: 32946039
Drug: Routine Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Western medicine
Study: 34775184
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) - any use
Study: 34775184
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum and nicotine patch used together
Study: 37431855
Drug: Oestrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen therapy
Study: 34664616
Drug: Sinovac‐CoronaVac vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinovac‐CoronaVac vaccine (2 doses, 28-day interval)
Study: 32154613
Drug: Atorvastatin (ATV)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (ATV) 10 mg
Study: 33941564
Drug: Both assays
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both assays at clinically diagnostic cutoffs (0.1, 0.25, 0.5, 2.0 ng/mL)
Study: 34164360
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (bLf) 100 mg twice a day orally during antibiotic therapy
Study: 34390076
Drug: Treatment matching
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment matching (preference for MBI-SAD or CBGT)
Study: 33677986
Drug: 3TC treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3TC treatment
Study: 35679810
Drug: Euhydration +
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euhydration + Treatment (ET)
Study: 35679810
Drug: Dehydration +
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dehydration + Treatment (DT)
Study: 33569574
Drug: Standard anti-hypertensive
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti-hypertensive therapy
Study: 32074335
Drug: Calmare Scrambler
Normalized name: UNDECYLENIC ACID 200 mg in 1 mL TOPICAL CREAM [NU CALMAR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calmare Scrambler Therapy (ST)
Study: 36038633
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no therapy)
Study: 34958174
Drug: VX-128 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-128 (100 mg once daily for up to 10 days)
Study: 34958174
Drug: VX-128 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-128 (multiple doses)
Study: 34958174
Drug: VX-128 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-128 (10 mg once daily)
Study: 34958174
Drug: VX-128 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-128 (10 and 30 mg once daily)
Study: 34222273
Drug: Assigned treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assigned treatments that match patient expectations
Study: 34837524
Drug: Flaxseed (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (30 g/day) plus regular diet (RF group)
Study: 34837524
Drug: Flaxseed (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (30 g/day) plus anti-inflammatory diet (AIF group)
Study: 34837524
Drug: Roasted wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roasted wheat (30 g/day) plus regular diet (RW group)
Study: 34080237
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg curcuminoids daily for 7 days
Study: 33759909
Drug: Colonoscopic polypectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonoscopic polypectomy without discontinuation of antithrombotic medication
Study: 33759909
Drug: Colonoscopic polypectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonoscopic polypectomy after discontinuation of antithrombotic medication
Study: 33317453
Drug: Pre-thickened oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-thickened oral nutritional supplements (ONS) with standard OD and nutritional care.
Study: 36763994
Drug: OC‐01 (varenicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC‐01 (varenicline solution) 0.03 mg
Study: 36388808
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate dispersible tablets with a 5-HT3 receptor antagonist and dexamethasone
Study: 33830462
Drug: Fully cemented
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully cemented TKA + intra‐articular injection (IAI) of 2 g TXA (n = 60)
Study: 33830462
Drug: Reverse hybrid
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reverse hybrid TKA + intra‐articular injection (IAI) of 1 g TXA (n = 56)
Study: 34965609
Drug: Cetagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetagliptin 50 mg
Study: 34655432
Drug: Cetagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetagliptin 100 mg
Study: 34965609
Drug: Cetagliptin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetagliptin 200 mg
Study: 34965609
Drug: Cetagliptin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetagliptin (all doses)
Study: 33709302
Drug: Tablet-based intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based intervention (daily self-care for pain, distress, fatigue, and sleep disturbance; weekly calls with a patient navigator)
Study: 35803709
Drug: Tablet-based intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-based intervention
Study: 33041442
Drug: Intravenous Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Abciximab
Study: 36385018
Drug: Substudy measuring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substudy measuring physiological changes (e.g., muscle mass, physical function) and patient experience (qualitative semi-structured interviews)
Study: 32590214
Drug: Therapy-as-usual (TAU)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy-as-usual (TAU)
Study: 35980349
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy (arm A)
Study: 32844586
Drug: Fermented dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented dairy products (cheese, sour cream)
Study: 32844586
Drug: Non-fermented dairy
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fermented dairy products (butter, whipped cream)
Study: 36539602
Drug: Traditional hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional hydration (Group I) at a rate of 1 ml/kg/h for 24 h
Study: 36539602
Drug: Modified hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified hydration (Group II) at a rate of 3 ml/kg/h for the first 4 h, then reduced to 1 ml/kg/h for 12 h
Study: 33524311
Drug: SCB-2019 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 (3 µg, 9 µg, or 30 µg) with AS03 adjuvant
Study: 33524311
Drug: SCB-2019 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 (3 µg, 9 µg, or 30 µg) with CpG/Alum adjuvant
Study: 33112661
Drug: Digital system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital system for electronic patient-reported outcomes (ePROs) administered weekly by web or automated telephone system
Study: 33715994
Drug: Control (mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (mannitol 50 mg)
Study: 32894159
Drug: Subacromial corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial corticosteroid injection then progressive exercise
Study: 32894159
Drug: Subacromial corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial corticosteroid injection then best practice advice
Study: 616505842
Drug: Combined supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplementation of 160 mug/d Cr plus 200 mg/d Mg
Study: 616505842
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d Mg
Study: 36131325
Drug: Azithromycin (10-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10-day intravenous treatment)
Study: 34319552
Drug: Favipiravir and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir and hydroxychloroquine combination therapy
Study: 36997260
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment
Study: 33555602
Drug: Being under
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Being under the influence of drugs or alcohol at the time of injury
Study: 35729675
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (500 mg of L.acidophilus, L.plantarum, L.fermentum, L.Gasseri and 38.5 mg of fructo‐oligo‐saccharides) for 6 weeks
Study: 35714273
Drug: Inactivated enterovirus
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated enterovirus 71 (EV71) vaccine, administered in two doses on day 0 and 28
Study: 33341239
Drug: Baseline hemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline hemoglobin <10 mg/dL
Study: 34129232
Drug: Probiotic supplement
Normalized name: Align Probiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplement containing Lactobacillus acidophilus and Bifidobacterium animalis lactis
Study: 35672178
Drug: FluCyD-vac (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: FluCyD-vac (9 μg of HA/strain and 20% w/v of HP-β-CyD)
Study: 35672178
Drug: Flu-vac (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu-vac (15 μg of HA/strain)
Study: 33427765
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg ibalizumab q2wk
Study: 33427765
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg ibalizumab weekly for 9 weeks, then q2wk
Study: 33534427
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of borage oil rich in gamma-linolenic acid + vitamin E (drug)
Study: 32342562
Drug: Genome Sequencing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genome Sequencing (GS) immediately with concurrent standard of care (SoC) testing
Study: 37003273
Drug: Ertugliflozin 5
Normalized name: ertugliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 5 mg
Study: 37003273
Drug: Ertugliflozin 15
Normalized name: ertugliflozin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin 15 mg
Study: 35874588
Drug: Incentive Spirometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive Spirometry (IS) - 30 breaths with sustained maximum inspiration twice daily for 8 weeks
Study: 33399410
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma treatment
Study: 33399410
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (topical glyceryl trinitrate)
Study: 34913089
Drug: Conservative fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative fluid administration and active deresuscitation (removal of accumulated fluid using diuretics or ultrafiltration)
Study: 32809843
Drug: Inhaled AZD1419
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled AZD1419 (1, 4, or 8 mg; n=40)
Study: 34462184
Drug: Formal physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formal physical therapy (PT)
Study: 35080681
Drug: No administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No administration of Utix sachets (control group)
Study: 34461742
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ITI-214
Study: 34461742
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ITI-214
Study: 34461742
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg ITI-214
Study: 36281666
Drug: Low-dose pioglitazone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pioglitazone
Study: 34340527
Drug: THX‐110 (Δ9‐THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: THX‐110 (Δ9‐THC 10 mg daily and PEA 800 mg daily)
Study: 32701984
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture treatment
Study: 36305633
Drug: CJM112 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJM112 300 mg
Study: 35746869
Drug: D1/D5-R antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1/D5-R antagonist (SCH-23390 hydrochloride)
Study: 35746869
Drug: D2/D3-R antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2/D3-R antagonist (Eticlopride hydrochloride)
Study: 35636696
Drug: Osimertinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib monotherapy (80 mg daily)
Study: 33888356
Drug: Intense neoadjuvant
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense neoadjuvant androgen deprivation therapy (ADT) followed by radical prostatectomy (RP)
Study: 34726574
Drug: V114 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: V114 administered concomitantly with QIV
Study: 34384427
Drug: My Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: My Therapy (self-management program)
Study: 33232647
Drug: Non-Negative Pressure
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Negative Pressure Wound Therapy (Non-NPWT)
Study: 33386530
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Chronic Pain (CBT‐CP) delivered either in person or by interactive voice response for 10 weeks
Study: 32957612
Drug: 336.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 336.4 mg of decaffeinated green tea catechins (GTC) after a single dose
Study: 32957612
Drug: 336.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 336.4 mg of decaffeinated green tea catechins (GTC) after 12 weeks of daily intake
Study: 33726718
Drug: ICG-hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICG-hyaluronic acid mixture 0.1 mL (Test Group 1)
Study: 35303118
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam
Study: 34657640
Drug: L-arabinose (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arabinose (7.5 g) co-ingested with 50 g sucrose
Study: 34657640
Drug: Control (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (50 g sucrose without L-arabinose)
Study: 32331937
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml sodium chloride 0.9 (placebo)
Study: 33908312
Drug: MR stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR stimulation (0.4 mg fludrocortisone + placebo)
Study: 33908312
Drug: NMDA-R stimulation
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMDA-R stimulation (placebo + 250 mg D-cycloserine)
Study: 33593332
Drug: Counseling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling and nicotine replacement for 8 weeks, plus ongoing proactive outreach calls inviting reengagement in treatment.
Study: 32321536
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy
Study: 35170228
Drug: Selumetinib granules
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib granules (25 mg) under fed conditions
Study: 35170228
Drug: Selumetinib capsules
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib capsules (50 mg [2 × 25 mg]) under fed conditions
Study: 35170228
Drug: Selumetinib capsules
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib capsules (50 mg [2 × 25 mg]) under fasted conditions
Study: 35170228
Drug: Selumetinib administration
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib administration with a low-fat meal
Study: 35220356
Drug: Simulated Electroconvulsive
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated Electroconvulsive Therapy (S-ECT)
Study: 34379607
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with 1.2g of protein plus high-protein supplement (36g whey protein)